Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S grew its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 170.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,404 shares of the life sciences company's stock after purchasing an additional 26,737 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Illumina were worth $5,666,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Golden State Wealth Management LLC acquired a new position in Illumina during the 4th quarter worth approximately $32,000. Versant Capital Management Inc grew its holdings in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Illumina in the fourth quarter worth $45,000. Assetmark Inc. lifted its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. acquired a new stake in Illumina in the fourth quarter valued at $48,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ILMN shares. Canaccord Genuity Group decreased their price objective on shares of Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a report on Tuesday, March 11th. Stephens reissued an "overweight" rating and set a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Barclays dropped their price objective on Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research note on Thursday, April 10th. Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Royal Bank of Canada dropped their price target on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Illumina currently has an average rating of "Moderate Buy" and an average price target of $138.70.

Illumina Trading Down 0.3 %

Illumina stock traded down $0.26 during trading on Friday, hitting $77.35. The company's stock had a trading volume of 1,424,483 shares, compared to its average volume of 2,280,770. The stock's fifty day moving average is $82.02 and its 200 day moving average is $118.20. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The stock has a market capitalization of $12.24 billion, a price-to-earnings ratio of -10.07, a P/E/G ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.